Lipocine Inc (LPCN) Stock Price, Quote & News

Company Profile

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation long-acting oral product candidate for TRT; LPCN 1148, a novel prodrug of testosterone and testosterone...

Industry: Biotechnology

Sector: Healthcare

Phone: 801 994 7383

Fax: 801 994 7388

Website: www.lipocine.com

Address:

675 Arapeen Drive, Suite 202, Salt Lake City, United States

RunningRobert1 Dec. 3 at 3:05 PM

$LPCN https://www.youtube.com/watch?v=qZdhpZi_mes Please join me for a Live Stream today were we will be looking at the best microcap stocks for 2026. If you see this it is because your stock is in the top 3

2 · Reply

amazingcrwns Nov. 26 at 7:32 PM

$LPCN We could always use some more volume, but I like that the price is holding up after the DSMB news last week. Its encouraging to still be in the 3+ range heading into Thanksgiving.

0 · Reply

chiefcoho Nov. 22 at 3:58 PM

$LPCN what needs to happen to get this to POP big news 30 cent stock move We need buyers

2 · Reply

merlin8121 Nov. 22 at 6:38 AM

$LPCN https://www.youtube.com/shorts/_DSnrdOwvBg

0 · Reply

Geraldbeak Nov. 18 at 8:44 PM

$LPCN Remember that the real success from todays news is the "no excessive sedation / loss of consiousness" being reported. If this safety data holds throughout phase 3 trials, upon approval, LPCN will likely see their share of the PPD market peak around 60-90% as a best in class, standard of care product. This was great news.

0 · Reply

slappyOpappy Nov. 18 at 6:56 PM

$LPCN I know we have a ways to go, but from my simpleton view I see an $18M market cap and a pipeline and results that are far from matching up....eventually. The PPD drug alone seems very promising

1 · Reply

BioAB Nov. 18 at 4:07 PM

$LPCN good stuff results. We just need to hold on.

1 · Reply

UnicornPicks Nov. 18 at 2:39 PM

$SGBX $NNOX $LPCN $ALMS

0 · Reply

RunningRobert1 Nov. 18 at 2:25 PM

$LPCN We have cleared another hurdle, with a clean safety report. Now its watch the stock go up and wait for data!

1 · Reply

steven1x Nov. 18 at 2:02 PM

$LPCN if missed https://www.prnewswire.com/news-releases/lipocine-highlights-promising-interim-safety-profile-in-phase-3-trial-of-lpcn-1154-in-postpartum-depression-ppd-302617859.html

2 · Reply

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Nov 6, 2025, 8:00 AM EST - 4 weeks ago

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025

Nov 4, 2025, 8:00 AM EST - 4 weeks ago

Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®

Sep 30, 2025, 8:00 AM EDT - 2 months ago

Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)

Sep 5, 2025, 4:30 PM EDT - 3 months ago

Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 26, 2025, 8:00 AM EDT - 3 months ago

Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025

Aug 5, 2025, 8:00 AM EDT - 4 months ago

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025

Jun 26, 2025, 8:00 AM EDT - 5 months ago

Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression

Jun 23, 2025, 8:00 AM EDT - 5 months ago

Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025

Jun 9, 2025, 8:00 AM EDT - 6 months ago

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada

May 22, 2025, 8:00 AM EDT - 7 months ago

Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology

May 14, 2025, 8:00 AM EDT - 7 months ago

Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase

May 8, 2025, 8:00 AM EDT - 7 months ago

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025

May 6, 2025, 8:00 AM EDT - 7 months ago

Lipocine Announces License and Supply Agreement for TLANDO® in Brazil

Mar 26, 2025, 8:00 AM EDT - 9 months ago

Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154

Mar 13, 2025, 8:00 AM EDT - 9 months ago

Lipocine Announces Financial Results for the Full Year Ended December 31, 2024

Mar 12, 2025, 8:00 AM EDT - 9 months ago

Lipocine Announces FDA Labeling Changes for Testosterone Products

Feb 6, 2025, 8:00 AM EST - 10 months ago

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

Dec 17, 2024, 8:00 AM EST - 1 year ago

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

Nov 18, 2024, 8:00 AM EST - 1 year ago

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session

Nov 7, 2024, 8:00 AM EST - 1 year ago

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea

Oct 10, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

Oct 8, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries

Oct 2, 2024, 8:00 AM EDT - 1 year ago

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024

Jun 25, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024

May 9, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024

May 8, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024

May 1, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

Mar 25, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

Mar 7, 2024, 8:00 AM EST - 1 year ago

Lipocine Announces Financial Results for the Full Year Ended December 31, 2023

Mar 6, 2024, 8:00 AM EST - 1 year ago

Lipocine to Present at 36th Annual Roth Conference

Feb 6, 2024, 8:00 AM EST - 1 year ago

Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154

Feb 2, 2024, 8:00 AM EST - 2 years ago

Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals

Jan 18, 2024, 8:00 AM EST - 2 years ago

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada

Dec 19, 2023, 8:00 AM EST - 2 years ago

Lipocine to Present at Biotech Showcase 2024

Nov 13, 2023, 2:45 PM EST - 2 years ago

Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023

Nov 8, 2023, 8:00 AM EST - 2 years ago

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023

Nov 1, 2023, 8:00 AM EDT - 2 years ago

Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023

Oct 26, 2023, 8:00 AM EDT - 2 years ago

Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression

Oct 23, 2023, 7:00 PM EDT - 2 years ago

Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference

Sep 19, 2023, 4:05 PM EDT - 2 years ago

Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference

Aug 10, 2023, 8:00 AM EDT - 2 years ago

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023

RunningRobert1 Dec. 3 at 3:05 PM

2 · Reply

amazingcrwns Nov. 26 at 7:32 PM

$LPCN We could always use some more volume, but I like that the price is holding up after the DSMB news last week. Its encouraging to still be in the 3+ range heading into Thanksgiving.

0 · Reply

chiefcoho Nov. 22 at 3:58 PM

$LPCN what needs to happen to get this to POP big news 30 cent stock move We need buyers

2 · Reply

merlin8121 Nov. 22 at 6:38 AM

$LPCN https://www.youtube.com/shorts/_DSnrdOwvBg

0 · Reply

Geraldbeak Nov. 18 at 8:44 PM

0 · Reply

slappyOpappy Nov. 18 at 6:56 PM

$LPCN I know we have a ways to go, but from my simpleton view I see an $18M market cap and a pipeline and results that are far from matching up....eventually. The PPD drug alone seems very promising

1 · Reply

BioAB Nov. 18 at 4:07 PM

$LPCN good stuff results. We just need to hold on.

1 · Reply

UnicornPicks Nov. 18 at 2:39 PM

$SGBX $NNOX $LPCN $ALMS

0 · Reply

RunningRobert1 Nov. 18 at 2:25 PM

$LPCN We have cleared another hurdle, with a clean safety report. Now its watch the stock go up and wait for data!

1 · Reply

steven1x Nov. 18 at 2:02 PM

$LPCN if missed https://www.prnewswire.com/news-releases/lipocine-highlights-promising-interim-safety-profile-in-phase-3-trial-of-lpcn-1154-in-postpartum-depression-ppd-302617859.html

2 · Reply

ITF Nov. 18 at 1:23 PM

$LPCN is this the real life, is this just fantasy, caught in a landslide , or escaped from ppd . Good news, let’s see a pop of interest

0 · Reply

DaBullRunner Nov. 18 at 1:10 PM

$LPCN watching……. 🚨COSM🚨 adding off that solid news 🚢📦📦📦 I’m even willing to put some of my COIN TSLA profits into COSM👇💰💰💰

0 · Reply

Tothemoonemoji Nov. 18 at 1:07 PM

$LPCN Safety data is positive!!!!

1 · Reply

Pedelco Nov. 18 at 9:16 AM

$LPCN 🎶🎸🎤🎼Got a real good feeling, got a real good feeling Like there is lighting deep in my bones

1 · Reply

amazingcrwns Nov. 17 at 3:26 PM

$LPCN I'm hoping we get the safety update from the DSMB safety review this week. It would be nice to get a new corp presentation and an update on the clinicaltrials website too but I imagine the FDA has quite a backlog to work through from the shutdown. I'm guessing the corp presentation update will come after the review. I'm not expecting it, but if we're lucky maybe the update will have some more information on when these FDA meetings might take place, ie 2401 fda regulatory meeting expected Q1 or something.

1 · Reply

Creisi Nov. 14 at 2:07 AM

$CSCO $FLY $LPCN $MLTX Puss off with your bullshit garbage stock. No one that invests in MLTX is interested in you polluting our message board with your bullshit trash. This is for MLTX only. Please f-off!

1 · Reply

aletz Nov. 13 at 3:31 PM

$LPCN https://www.biostockinfo.com/biotech-catalyst-ai-scanner-november-wk3/ LPCN listed 7th on the AI scanner, hope the recovery momentum continues

0 · Reply

JarvisFlow Nov. 13 at 12:55 PM

HC Wainwright & Co. has updated their rating for Lipocine ( $LPCN ) to Buy with a price target of 7.

1 · Reply

Pedelco Nov. 12 at 9:24 PM

$LPCN I luv my Lipo

0 · Reply

amazingcrwns Nov. 12 at 8:45 PM

$LPCN I'm still not sure if the safety update after the DSMB review is going to be a typical sell the news catalyst or the start of the climb to results. Curious what others here think, are you anticipating a brief boost in share price and drift back down again or will it be the start of the slow climb to topline results?

2 · Reply

aah98a Nov. 11 at 4:57 PM

$LPCN The next few months should be interesting. I still believe partnership is coming for LPCN 1154. Any thoughts on that?

1 · Reply

RunningRobert1 Nov. 10 at 2:40 PM

$LPCN Lipocine Inc LPCN Q3 2025 Summary 10Nov2025 https://youtu.be/asck5yZgJ9M As you know this is one of my 2026 targets, I can safely say as we get closer to data we should see a easy double, based on the fact that the other PPD drug is making some good headways and they think it can be a 1B drug.

2 · Reply

Market Cap	17.49M
Revenue (ttm)	11.20M
Net Income (ttm)	10,000.00
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.09%
Debt to Equity Ratio	0.00

Volume	26,300
Avg Vol	50,602
Day's Range	N/A - N/A
Shares Out	5.55M
Stochastic %K	35%
Beta	1.03
Analysts	Sell
Price Target	$6.88